The dual function of autophagy in tumorigenesis and the implications of autophagy modulation for cancer therapy are also discussed.”
“Aims: The utility of fenestrated-endovascular aneurysm repair (FEVAR) remains uncertain. This study examines the medium term outcomes of patients undergoing FEVAR for asymptomatic juxtarenal abdominal aortic aneurysm (AAA).

Methods: Consecutive patients undergoing elective FEVAR for juxtarenal AAA at a single tertiary centre were studied between October 2005 and March 2010. Patients were followed up for at least six-months within a protocol including clinical examination, laboratory studies,

CT and duplex imaging, and abdominal radiographs. Outcomes were assessed in terms of survival, target vessel patency Selleckchem AZD2014 and graft related complications.

Results: Twenty-nine patients were analysed on an intention to treat basis. There were 27 men and two women of median (range) age 74 (54-86) years. Mean (SD) aneurysm diameter was 68 (7) mm. Median (range) ASA score was 3 (2-4). No procedures required conversion to an open procedure, but one procedure was abandoned. Seventy-nine visceral vessels were perfused through a fabric fenestration

or scallop. All vessels remained patent at MAPK Inhibitor Library completion angiography. No patients died within 30-days of surgery. During follow up there were four (14%) deaths at a median (range) of 17 (8-21) months after aneurysm repair. None of these deaths Napabucasin JAK/STAT inhibitor were aneurysm related. Eighteen (62%) patients suffered one or more graft related complications, of whom 11 (38%) required one or more early or late reintervention.

Conclusions: Fenestrated aortic endografts can be utilized safely in the management of juxtarenal AAA in patients at high-risk for open surgery. However, the rate of graft related complication and reintervention is high at medium term follow up. (C) 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.”
“Objective: To evaluate the effect of anti-VEGF (bevacizumab) injection to the

posterior chamber (BIPC) behind the iris combined with seton implantation in treatment of neovascular glaucoma (NVG).

Methods: Twenty-eight eyes with NVG who underwent BIPC, prospectively evaluated. Anterior segment photographs were taken for grading of neovascularization on anterior segment in pretreatment period and at each follow-up. Grading and regression of rubeosis iridis was classified according to Teich and Walsh grading system and glaucoma filtration surgery with drainage device was performed following BIPC.

Results: The mean pre-BIPC IOP was 39.71 +/- 7.09 mmHg, post-BIPC IOP in the 1st, 2nd day, 1st week, 1st, 3rd, 6th month were 19.7 +/- 8.9 mmHg, 13.5 +/- 6.7 mmHg, 9.9 +/- 3.4 mmHg, 13.07 +/- 5.3 mmHg, 16.6 +/- 5.03 mmHg, 18.5 +/- 3.8 mmHg, respectively. Twenty seven eyes underwent seton implantation surgery.